We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-22.52%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.18B
AUM Growth
-$1.05B
Cap. Flow
-$488M
Cap. Flow %
-41.25%
Top 10 Hldgs %
68.01%
Holding
52
New
5
Increased
2
Reduced
19
Closed
12

Top Buys

Rank Stock Value
1
WGS icon
GeneDx Holdings
WGS
+$23.5M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$9.77M
3
ABCL icon
AbCellera Biologics
ABCL
+$6.35M
4
CLDX icon
Celldex Therapeutics
CLDX
+$4.79M
5
RLAY icon
Relay Therapeutics
RLAY
+$4.53M

Top Sells

Rank Stock Value
1
PACB icon
Pacific Biosciences
PACB
+$72.7M
2
NVTA
Invitae Corporation
NVTA
+$49.4M
3
EXAS
Exact Sciences
EXAS
+$47.1M
4
CDNA icon
CareDx
CDNA
+$42.7M
5
FATE icon
Fate Therapeutics
FATE
+$35.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABCL icon
26
AbCellera Biologics
ABCL
$1.78B
$7.99M 0.68%
+750,000
New +$6.35M
EXAI
27
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$7.23M 0.61%
663,900
-50,000
-7% -$597K
MRTX
28
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$6.51M 0.55%
97,000
-5,500
-5% -$350K
GLUE icon
29
Monte Rosa Therapeutics
GLUE
$1.3B
$4.94M 0.42%
510,882
-450,000
-47% -$4.52M
CLDX icon
30
Celldex Therapeutics
CLDX
$2.96B
$4.45M 0.38%
+165,000
New +$4.79M
PMVP icon
31
PMV Pharmaceuticals
PMVP
$59.7M
$4.28M 0.36%
+300,000
New +$4.37M
SGMO
32
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$4.14M 0.35%
+1,000,000
New +$4.32M
FDMT icon
33
4D Molecular Therapeutics
FDMT
$527M
$3.88M 0.33%
555,455
– –
OMIC
34
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$3.31M 0.28%
28,857
-19,239
-40% -$2.26M
DNTH icon
35
Dianthus Therapeutics
DNTH
$5.8B
$2.9M 0.25%
150,938
-22,404
-13% -$554K
ORIC icon
36
Oric Pharmaceuticals
ORIC
$1.1B
$2.69M 0.23%
601,515
– –
NVTA
37
DELISTED
Invitae Corporation
NVTA
$2.53M 0.21%
1,038,388
-11,165,281
-91% -$49.4M
SNCE
38
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$452K 0.04%
11,250
-78,750
-88% -$5.75M
KRON
39
DELISTED
Kronos Bio
KRON
$451K 0.04%
123,839
-459,597
-79% -$2.08M
LIAN
40
DELISTED
LianBio American Depositary Shares
LIAN
$446K 0.04%
206,415
– –
ADPT icon
41
Adaptive Biotechnologies
ADPT
$3.68B
– –
-1,000,000
Closed -$13.9M
CDNA icon
42
CareDx
CDNA
$2.48B
– –
-1,153,335
Closed -$42.7M
CDXS icon
43
Codexis
CDXS
$156M
– –
-300,000
Closed -$6.19M
DNA icon
44
Ginkgo Bioworks
DNA
$584M
– –
-105,070
Closed -$16.9M
GBIO
45
DELISTED
Generation Bio
GBIO
– –
-132,428
Closed -$9.72M
PACB icon
46
Pacific Biosciences
PACB
$441M
– –
-7,990,652
Closed -$72.7M
RXRX icon
47
Recursion Pharmaceuticals
RXRX
$1.69B
– –
-548,156
Closed -$3.92M
SEER icon
48
Seer Inc
SEER
$123M
– –
-800,000
Closed -$12.2M
ZLAB icon
49
Zai Lab
ZLAB
$2.05B
– –
-150,000
Closed -$6.6M
ONC
50
BeOne Medicines Ltd
ONC
$32.6B
– –
-150,000
Closed -$28.3M
1
2
3

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q2 2022 Portfolio in Review

As of Q2 2022, Casdin Capital held 52 positions worth $1.18B, down 47% from $2.23B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Casdin Capital withdrew a net $488M in Q2 2022, closing 12 positions and reducing 19 holdings. Its most notable exit was Pacific Biosciences, an estimated $72.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 96% a quarter earlier.

Against the trend, Casdin Capital opened a new position in Karuna Therapeutics, Inc. Common Stock worth $10.8M.

  • Casdin Capital's largest Q2 2022 buy was Karuna Therapeutics, Inc. Common Stock: 85,000 shares worth $10.8M.
  • Casdin Capital added most to GeneDx Holdings in Q2 2022, an estimated $23.5M increase.
  • Casdin Capital's biggest Q2 2022 reduction was Invitae Corporation, cutting an estimated $49.4M.
  • Casdin Capital fully exited Pacific Biosciences in Q2 2022, selling an estimated $72.7M.
  • Casdin Capital's ten largest holdings make up 68% of its $1.18B portfolio in Q2 2022.
  • Casdin Capital opened 5 new positions and closed 12 in Q2 2022.
  • Casdin Capital's portfolio value fell 47% quarter-over-quarter to $1.18B.

Based on Casdin Capital's 13F filing for Q2 2022, filed 15 Aug 2022.